Copied


Moderna (MRNA) Stock Price Prediction: Analyst targets clash with a weak technical tape as momentum cools

Felix Pinkston   Nov 18, 2026 12:46 0 Min Read


Price action: firm headline, softer tape

Moderna (MRNA) ended the latest session at $206.80, with Yahoo Finance showing a 3.93% drop at the close on November 17 and a slightly firmer overnight print at $207.32. The stock’s immediate setup is less about a clean breakout and more about whether buyers can absorb a pullback that has left price below the short and medium moving averages.

The current quote sits under the 7-day SMA at $217.86, the 50-day SMA at $219.38, and the 20-day SMA at $233.58. That is not a bullish trend structure; it is a market that has been stretched lower from its near-term averages and is now trying to stabilize.

What the indicators are saying

Momentum is mixed but not broken. The daily RSI at 42.05 is neutral, which means the stock is not washed out, but neither is it showing strong upward traction. The MACD is negative at -0.9112, with a flat histogram, which points to fading downside momentum rather than a confirmed reversal.

The most important near-term technical detail is location. MRNA is trading near the lower Bollinger Band at $196.11, with %B at 0.1596. That usually signals price is pressing into the lower part of its recent range, where mean reversion can appear if sellers lose control. The 14-day ATR of $17.29 also says volatility remains high enough that intraday swings can easily overshoot obvious levels.

Support, resistance and the current trade map

The first line of defense is immediate support at $200.70, with stronger support at $193.33. On the upside, the market needs to reclaim the pivot at $211.48, then the immediate resistance at $218.85, before the stronger ceiling at $229.63 comes into play.

The moving-average structure still leans defensive: short-term distribution, with the 7-day average below the 20-day average. At the same time, the stock is now deeply discounted below the 20-day average, which opens the door to a reflex bounce if volume improves.

Analyst targets frame the fundamental debate

On the research side, the story is split. Morgan Stanley maintained Equal-Weight and raised its target to $200 from $95 on November 17. JPMorgan lifted its target to $102 from $77 while keeping Underweight, tying the move to Moderna’s expense outlook and updated guidance. Separately, the broader S&P Global analyst poll cited by stockanalysis.com shows 23 analysts with a consensus Hold and an average target of $165.32, with a low of $45 and a high of $305.

That range matters because it shows the market is not agreed on how much of Moderna’s longer-term growth case is already embedded in the stock. Yahoo Finance says the investment case now centers on personalized melanoma vaccine intismeran after Phase 3 data showed a meaningful reduction in recurrence or death, alongside stronger third-quarter results and raised 2026 revenue guidance. The market is still testing whether those drivers can outweigh the valuation burden and the execution risk around future launches.

Derivatives positioning points to activity, not certainty

Binance perpetual futures data shows funding at 0.0000%, so positioning is not being skewed by an obvious crowding payment signal. Open interest rose 9.66% in 24 hours to 14,520.33 contracts, with open interest value at $3.27 million, which suggests new positioning is building.

The flow mix is slightly constructive but not decisive. Binance global accounts show 50.7% long versus 49.3% short, and top-trader accounts are almost perfectly balanced at 50.2% long versus 49.8% short. More telling is the taker buy/sell ratio of 1.4979, with buy volume of 402 against sell volume of 269. That points to aggressive buying pressure in the futures tape, but it does not by itself prove sustained upside in the underlying equity.

Conditional setup

If MRNA can reclaim $211.48 and hold above it, the next test is $218.85, where the first meaningful resistance sits close to the 7-day and 50-day moving averages. Failure to hold $200.70 leaves $193.33 exposed, and a break there would confirm that the lower-Bollinger-band setup is no longer acting as support.

The cleaner read right now is this: the stock is not in a confirmed downtrend collapse, but it is still trading below key trend markers, and the burden is on buyers to turn the current low-volume pullback into a durable base.


Read More